{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:13:12Z","timestamp":1790053992608,"version":"4.0.1"},"reference-count":196,"publisher":"Georg Thieme Verlag KG","issue":"06","funder":[{"name":"Bart McLean Fund"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 NS1101112"],"award-info":[{"award-number":["R01 NS1101112"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 NS123712"],"award-info":[{"award-number":["R01 NS123712"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neurosarcoidosis is a rare but clinically significant manifestation of sarcoidosis, often presenting with diverse neurologic symptoms that can lead to permanent disability if left untreated. This review aims to provide internists, pulmonologists, nonneurologist clinicians, and critical care specialists with a structured, pragmatic approach to the evaluation, diagnosis, and management of neurosarcoidosis in two distinct patient groups: those with a known diagnosis of systemic sarcoidosis and those with no prior history of sarcoidosis. We emphasize the recognition of key acute clinical syndromes such as seizures, stroke, neuroendocrinopathy, hydrocephalus, meningeal disease, myelopathy, and infectious complications that may be encountered in emergency and critical care scenarios. The management approach, which includes first-line therapies such as glucocorticoids and immunomodulatory treatments such as TNF inhibitors and IL-6 inhibitors, is now accepted in the critical care setting to minimize the development of long-standing neurological complications associated with neurosarcoidosis. Furthermore, there is a critical need for a safe and effective transition to steroid-sparing medications for long-term disease control, while closely monitoring the risk for infections, such as tuberculosis and opportunistic infections, metabolic disturbances, and other complications. Given the significance of neurosarcoidosis as a severe manifestation of systemic sarcoidosis, a multidisciplinary approach is essential to effectively manage both neurological and systemic manifestations.<\/jats:p>","DOI":"10.1055\/a-2768-3052","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T23:58:48Z","timestamp":1765411128000},"page":"622-640","source":"Crossref","is-referenced-by-count":2,"title":["Neurosarcoidosis in Critical Care, Internal, and Pulmonary Medicine: A Practical Approach"],"prefix":"10.1055","volume":"46","author":[{"given":"Munther M.","family":"Queisi","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Pardo","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Neurological Infections, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States"},{"name":"Division of Neuropathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1164\/rccm.202002-0251ST","article-title":"Diagnosis and detection of sarcoidosis. An Official American Thoracic Society clinical practice guideline","volume":"201","author":"E D Crouser","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"ref2","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.3390\/jcm10132857","article-title":"A primer on the clinical aspects of sarcoidosis for the basic and translational scientist","volume":"10","author":"M A Judson","year":"2021","journal-title":"J Clin Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"577871","DOI":"10.1016\/j.jneuroim.2022.577871","article-title":"Clinical features and diagnosis of neurosarcoidosis - review article","volume":"368","author":"P Barreras","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"e1084","DOI":"10.1212\/NXI.0000000000001084","article-title":"Neurosarcoidosis: pathophysiology, diagnosis, and treatment","volume":"8","author":"M J Bradshaw","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/19418744211030416","article-title":"Isolated CNS sarcoidosis versus systemic sarcoidosis with CNS involvement: a same disease?","volume":"12","author":"E Courtin","year":"2022","journal-title":"Neurohospitalist"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccm.2023.08.005","article-title":"Neurosarcoidosis and neurologic complications of sarcoidosis treatment","volume":"45","author":"M Voortman","year":"2024","journal-title":"Clin Chest Med"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s11882-023-01092-z","article-title":"Neurosarcoidosis: diagnostic challenges and mimics a review","volume":"23","author":"J Shen","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"issue":"01","key":"ref8","doi-asserted-by":"crossref","first-page":"6539","DOI":"10.1038\/s41598-023-33631-z","article-title":"A comprehensive diagnostic approach in suspected neurosarcoidosis","volume":"13","author":"S G Berntsson","year":"2023","journal-title":"Sci Rep"},{"issue":"09","key":"ref9","doi-asserted-by":"crossref","first-page":"e3443","DOI":"10.1002\/brb3.3443","article-title":"Neurosarcoidosis: clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort","volume":"14","author":"A Dos Santos","year":"2024","journal-title":"Brain Behav"},{"issue":"04","key":"ref10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1055\/s-0037-1602845","article-title":"Sarcoidosis around the globe","volume":"38","author":"K Mateyo","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"issue":"06","key":"ref11","first-page":"1052","article-title":"Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants","volume":"37","author":"P Brito-Zer\u00f3n","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"06","key":"ref12","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/joim.13629","article-title":"Sarcoidosis: epidemiology and clinical insights","volume":"293","author":"M Rossides","year":"2023","journal-title":"J Intern Med"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.21037\/jtd-23-192","article-title":"Diagnosis of pulmonary sarcoidosis in tuberculosis endemic area-a narrative review","volume":"15","author":"T Sodsri","year":"2023","journal-title":"J Thorac Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-030-68748-9_3","article-title":"Inflammatory pathways in sarcoidosis","volume":"1304","author":"B P Barna","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"e175264","DOI":"10.1172\/JCI175264","article-title":"Immune mechanisms of granuloma formation in sarcoidosis and tuberculosis","volume":"134","author":"P Weeratunga","year":"2024","journal-title":"J Clin Invest"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"103247","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"J Miedema","year":"2024","journal-title":"J Autoimmun"},{"issue":"06","key":"ref18","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.it.2024.04.013","article-title":"Sarcoidosis immunopathogenesis - a new concept of maladaptive trained immunity","volume":"45","author":"M Robert","year":"2024","journal-title":"Trends Immunol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"577957","DOI":"10.1016\/j.jneuroim.2022.577957","article-title":"Genetics of neurosarcoidosis","volume":"372","author":"A Hardin","year":"2022","journal-title":"J Neuroimmunol"},{"issue":"S 06","key":"ref20","doi-asserted-by":"crossref","first-page":"S429","DOI":"10.1513\/AnnalsATS.201707-565OT","article-title":"Genetic, immunologic, and environmental basis of sarcoidosis","volume":"14","author":"D R Moller","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12931-021-01818-5","article-title":"Associations between occupational and environmental exposures and organ involvement in sarcoidosis: a retrospective case-case analysis","volume":"22","author":"S Ronsmans","year":"2021","journal-title":"Respir Res"},{"issue":"09","key":"ref22","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1513\/AnnalsATS.202208-722OC","article-title":"Identification of environmental exposures associated with risk of sarcoidosis in African Americans","volume":"20","author":"A M Levin","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"103239","DOI":"10.1016\/j.jaut.2024.103239","article-title":"Infectious and non-infectious precipitants of sarcoidosis","volume":"149","author":"O S Chioma","year":"2024","journal-title":"J Autoimmun"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMra2101555","article-title":"Challenges of sarcoidosis and its management","volume":"385","author":"M Drent","year":"2021","journal-title":"N Engl J Med"},{"issue":"01","key":"ref25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.chest.2017.10.014","article-title":"Clinical course of sarcoidosis in world trade center-exposed firefighters","volume":"153","author":"K M Hena","year":"2018","journal-title":"Chest"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/ACI.0b013e3283515173","article-title":"Occupational causes of sarcoidosis","volume":"12","author":"K L Newman","year":"2012","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1055\/s-0030-1262205","article-title":"The etiologic role of infectious antigens in sarcoidosis pathogenesis","volume":"31","author":"K A Oswald-Richter","year":"2010","journal-title":"Semin Respir Crit Care Med"},{"issue":"03","key":"ref28","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1365-2249.2007.03510.x","article-title":"Multiple mycobacterium antigens induce interferon-gamma production from sarcoidosis peripheral blood mononuclear cells","volume":"150","author":"J Carlisle","year":"2007","journal-title":"Clin Exp Immunol"},{"issue":"01","key":"ref29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1128\/IAI.00732-06","article-title":"Cellular recognition of mycobacterium tuberculosis ESAT-6 and KatG peptides in systemic sarcoidosis","volume":"75","author":"W P Drake","year":"2007","journal-title":"Infect Immun"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00408-019-00243-2","article-title":"How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants","volume":"197","author":"M Ramos-Casals","year":"2019","journal-title":"Lung"},{"issue":"06","key":"ref31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.201503-0418OC","article-title":"Identification of immune-relevant factors conferring sarcoidosis genetic risk","volume":"192","author":"A Fischer","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"04","key":"ref32","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccm.2015.08.002","article-title":"Genetics of sarcoidosis","volume":"36","author":"T E Fingerlin","year":"2015","journal-title":"Clin Chest Med"},{"issue":"16","key":"ref33","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1093\/hmg\/ddad067","article-title":"Genome-wide association study identifies multiple HLA loci for sarcoidosis susceptibility","volume":"32","author":"S Y Liao","year":"2023","journal-title":"Hum Mol Genet"},{"issue":"08","key":"ref34","doi-asserted-by":"crossref","first-page":"e43907","DOI":"10.1371\/journal.pone.0043907","article-title":"Genome-wide association study of African and European Americans implicates multiple shared and ethnic specific loci in sarcoidosis susceptibility","volume":"7","author":"I Adrianto","year":"2012","journal-title":"PLoS One"},{"issue":"20","key":"ref35","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1093\/hmg\/ddq325","article-title":"Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups","volume":"19","author":"H Sato","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"07","key":"ref36","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.humimm.2005.04.003","article-title":"Severe pulmonary sarcoidosis is strongly associated with the haplotype HLA-DQB1*0602-DRB1*150101","volume":"66","author":"C E Voorter","year":"2005","journal-title":"Hum Immunol"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1513\/AnnalsATS.202007-874CME","article-title":"Summary for clinicians: clinical practice guideline for the diagnosis and detection of sarcoidosis","volume":"17","author":"A Singha","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jcmg.2025.02.010","article-title":"Global practices in cardiac imaging for cardiac sarcoidosis: a survey study of International Experts with Delphi Consensus","volume":"18","author":"T S Kafil","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"131853","DOI":"10.1016\/j.ijcard.2024.131853","article-title":"Diagnostic and management strategies in cardiac sarcoidosis","volume":"403","author":"J K Malhi","year":"2024","journal-title":"Int J Cardiol"},{"issue":"04","key":"ref40","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1097\/WNO.0000000000001108","article-title":"Neuro-ophthalmic manifestations of sarcoidosis","volume":"41","author":"A D Henderson","year":"2021","journal-title":"J Neuroophthalmol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajo.2021.03.047","article-title":"Classification Criteria for Sarcoidosis-Associated Uveitis","volume":"228","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"ref42","doi-asserted-by":"crossref","first-page":"796.e1","DOI":"10.1016\/j.crad.2020.05.008","article-title":"Retrospective, dual-centre review of imaging findings in neurosarcoidosis at presentation: prevalence and imaging sub-types","volume":"75","author":"G Bathla","year":"2020","journal-title":"Clin Radiol"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1212\/NXI.0000000000000722","article-title":"Clinical and MRI phenotypes of sarcoidosis-associated myelopathy","volume":"7","author":"O C Murphy","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00415-024-12868-2","article-title":"Cerebral vasculitis related to neurosarcoidosis: a case series and systematic literature review","volume":"272","author":"J K Focke","year":"2025","journal-title":"J Neurol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"123080","DOI":"10.1016\/j.jns.2024.123080","article-title":"Stroke associated with sarcoidosis: a systematic review of reported cases","volume":"462","author":"D KA Pua","year":"2024","journal-title":"J Neurol Sci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"105040","DOI":"10.1016\/j.msard.2023.105040","article-title":"Hydrocephalus in neurosarcoidosis: clinical course, radiographic accompaniments, and experience with shunting","volume":"79","author":"S El Sammak","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"05","key":"ref47","first-page":"220","article-title":"Clinical significance of soluble interleukin-2 receptor measurement in immune-mediated diseases","volume":"78","author":"W A Dik","year":"2020","journal-title":"Neth J Med"},{"issue":"07","key":"ref48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/17476348.2020.1751614","article-title":"Value of serum soluble interleukin-2 receptor as a diagnostic and predictive biomarker in sarcoidosis","volume":"14","author":"M C Schimmelpennink","year":"2020","journal-title":"Expert Rev Respir Med"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"8565423","DOI":"10.1155\/2019\/8565423","article-title":"Prognostic biomarkers of sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6","volume":"2019","author":"L Bergantini","year":"2019","journal-title":"Dis Markers"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-019-1263-z","article-title":"Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis","volume":"21","author":"D Bennett","year":"2020","journal-title":"Respir Res"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/11795735241274186","article-title":"Diagnostic value of soluble Interleukin-2 receptor in patients suffering neurosarcoidosis: A systematic review","volume":"16","author":"A Chanpura","year":"2024","journal-title":"J Cent Nerv Syst Dis"},{"issue":"10","key":"ref52","doi-asserted-by":"crossref","first-page":"e0223897","DOI":"10.1371\/journal.pone.0223897","article-title":"Sensitivity and specificity of serum soluble interleukin-2 receptor for diagnosing sarcoidosis in a population of patients suspected of sarcoidosis","volume":"14","author":"L EM Eurelings","year":"2019","journal-title":"PLoS One"},{"key":"ref53","first-page":"1290","article-title":"Chronic and subacute meningitis","volume":"18","author":"J R Zunt","year":"2012","journal-title":"Continuum (Minneap Minn)"},{"issue":"01","key":"ref54","doi-asserted-by":"publisher","first-page":"e200184","DOI":"10.1212\/nxi.0000000000200184","article-title":"Tuberculous Meningitis or Neurosarcoidosis-a Diagnostic Quandary. From the National Multiple Sclerosis Society Case Conference Proceedings. Neurology(R) neuroimmunology & neuroinflammation","volume":"11","author":"J Lin","year":"2024","journal-title":"Jan"},{"issue":"02","key":"ref55","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41571-024-00970-3","article-title":"Leptomeningeal metastatic disease: new frontiers and future directions","volume":"22","author":"A Ozair","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"01","key":"ref56","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1212\/NXI.0000000000000425","article-title":"Pleocytosis is not fully responsible for low CSF glucose in meningitis","volume":"5","author":"M O Baud","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"578394","DOI":"10.1016\/j.jneuroim.2024.578394","article-title":"Beyond biopsy for neurosarcoidosis: a review of blood and CSF biomarkers","volume":"393","author":"E Lackey","year":"2024","journal-title":"J Neuroimmunol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.05.020","article-title":"Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of neurosarcoidosis","volume":"285","author":"C Bridel","year":"2015","journal-title":"J Neuroimmunol"},{"issue":"04","key":"ref59","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1212\/NXI.0000000000000725","article-title":"Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis","volume":"7","author":"C Otto","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"07","key":"ref60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.nmd.2022.05.012","article-title":"Clinical characteristics and outcome in muscular sarcoidosis: a retrospective cohort study and literature review","volume":"32","author":"L Ten Dam","year":"2022","journal-title":"Neuromuscul Disord"},{"issue":"08","key":"ref61","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1002\/jcu.23759","article-title":"Non-negligible ultrasonographic findings in sarcoid myositis: a case series and literature review","volume":"52","author":"P P Lv","year":"2024","journal-title":"J Clin Ultrasound"},{"issue":"12","key":"ref62","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaneurol.2018.2295","article-title":"Definition and consensus diagnostic criteria for neurosarcoidosis: from the neurosarcoidosis consortium consensus group","volume":"75","author":"B J Stern","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"577653","DOI":"10.1016\/j.jneuroim.2021.577653","article-title":"Aseptic meningitis and leptomeningeal enhancement associated with anti-MOG antibodies: a review","volume":"358","author":"G Y Gombolay","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/MAO.0000000000000501","article-title":"Cranial base manifestations of neurosarcoidosis: a review of 305 patients","volume":"36","author":"M L Carlson","year":"2015","journal-title":"Otol Neurotol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"578529","DOI":"10.1016\/j.jneuroim.2025.578529","article-title":"Predictors of visual outcome in optic neuropathy of sarcoidosis","volume":"400","author":"A S Nakirikanti","year":"2025","journal-title":"J Neuroimmunol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"117282","DOI":"10.1016\/j.jns.2020.117282","article-title":"A multi-center case series of sarcoid optic neuropathy","volume":"420","author":"L M Webb","year":"2021","journal-title":"J Neurol Sci"},{"issue":"05","key":"ref67","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1212\/NXI.0000000000000270","article-title":"Optic neuropathy associated with systemic sarcoidosis","volume":"3","author":"D P Kidd","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"120035","DOI":"10.1016\/j.jns.2021.120035","article-title":"Optic perineuritis: A Canadian case series and literature review","volume":"430","author":"J S Xie","year":"2021","journal-title":"J Neurol Sci"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000481681","article-title":"The protean neuropsychiatric and vestibuloauditory manifestations of neurosarcoidosis","volume":"22","author":"J J Greene","year":"2017","journal-title":"Audiol Neurootol"},{"issue":"09","key":"ref70","doi-asserted-by":"crossref","first-page":"e209955","DOI":"10.1212\/WNL.0000000000209955","article-title":"Pearls & oy-sters: vocal cord palsy as the presenting manifestation of neurosarcoidosis","volume":"103","author":"S Iyer","year":"2024","journal-title":"Neurology"},{"issue":"02","key":"ref71","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/0003489420942546","article-title":"Neurosarcoidosis directly involving the cervical vagus nerve","volume":"130","author":"J R Crossley","year":"2021","journal-title":"Ann Otol Rhinol Laryngol"},{"issue":"09","key":"ref72","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1007\/s00415-023-11782-3","article-title":"Tumefactive brain parenchymal neurosarcoidosis","volume":"270","author":"G A Bou","year":"2023","journal-title":"J Neurol"},{"issue":"11","key":"ref73","doi-asserted-by":"crossref","first-page":"e213705","DOI":"10.1212\/WNL.0000000000213705","article-title":"Factors associated with relapse in patients with neurosarcoidosis","volume":"104","author":"L Nitsch","year":"2025","journal-title":"Neurology"},{"issue":"01","key":"ref74","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11102-015-0678-x","article-title":"Hypothalamic-pituitary sarcoidosis with vision loss and hypopituitarism: case series and literature review","volume":"19","author":"J Anthony","year":"2016","journal-title":"Pituitary"},{"issue":"10","key":"ref75","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/qjmed\/hcs121","article-title":"Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients","volume":"105","author":"C Langrand","year":"2012","journal-title":"QJM"},{"issue":"08","key":"ref76","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00415-018-8928-2","article-title":"Sarcoidosis of the central nervous system: clinical features, imaging, and CSF results","volume":"265","author":"D P Kidd","year":"2018","journal-title":"J Neurol"},{"issue":"06","key":"ref77","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/ene.15295","article-title":"Clinical characteristics and outcome of neurosarcoidosis-associated myelitis: a retrospective cohort study and review of the literature","volume":"29","author":"J YC Nolte","year":"2022","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3174\/ajnr.A7724","article-title":"Spinal cord sarcoidosis occurring at sites of spondylotic stenosis, mimicking spondylotic myelopathy: a case series and review of the literature","volume":"44","author":"R M Kurtz","year":"2023","journal-title":"AJNR Am J Neuroradiol"},{"issue":"01","key":"ref79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1212\/CON.0000000000001390","article-title":"Clinical approach to myelopathy diagnosis","volume":"30","author":"C A Pardo","year":"2024","journal-title":"Continuum (Minneap Minn)"},{"issue":"03","key":"ref80","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/CON.0000000000001438","article-title":"The neurocritical care examination and workup","volume":"30","author":"S Wahlster","year":"2024","journal-title":"Continuum (Minneap Minn)"},{"issue":"03","key":"ref81","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1212\/CON.0000000000001445","article-title":"Emergent management of status epilepticus","volume":"30","author":"C Rubinos","year":"2024","journal-title":"Continuum (Minneap Minn)"},{"issue":"05","key":"ref82","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1212\/CON.0000000000000988","article-title":"Management of cerebral edema, brain compression, and intracranial pressure","volume":"27","author":"E M Liotta","year":"2021","journal-title":"Continuum (Minneap Minn)"},{"issue":"05","key":"ref83","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s00415-021-10882-2","article-title":"Clinical characteristics and outcome of hydrocephalus in neurosarcoidosis: a retrospective cohort study and review of the literature","volume":"269","author":"L Ten Dam","year":"2022","journal-title":"J Neurol"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12883-016-0741-x","article-title":"Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis","volume":"16","author":"D Fritz","year":"2016","journal-title":"BMC Neurol"},{"issue":"02","key":"ref85","doi-asserted-by":"crossref","first-page":"e200429","DOI":"10.1212\/CPJ.0000000000200429","article-title":"Consensus recommendations for the management of neurosarcoidosis: a Delphi survey of experts across the United States","volume":"15","author":"G S Manzano","year":"2025","journal-title":"Neurol Clin Pract"},{"issue":"04","key":"ref86","doi-asserted-by":"crossref","first-page":"103528","DOI":"10.1016\/j.autrev.2024.103528","article-title":"Cerebral vasculitis as a clinical manifestation of neurosarcoidosis: a scoping review","volume":"23","author":"Y Winter","year":"2024","journal-title":"Autoimmun Rev"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"104227","DOI":"10.1016\/j.msard.2022.104227","article-title":"Ischemic stroke in neurosarcoidosis: a retrospective cohort analysis","volume":"68","author":"S K Hutto","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"02","key":"ref88","doi-asserted-by":"crossref","first-page":"e200196","DOI":"10.1212\/NXI.0000000000200196","article-title":"Cardiac involvement in neurosarcoidosis: a single-center investigation","volume":"11","author":"S Noroozi Gilandehi","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"ref89","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1007\/s00415-018-9001-x","article-title":"Clinical, imaging, and histological presentations and outcomes of stroke related to sarcoidosis","volume":"265","author":"V Jachiet","year":"2018","journal-title":"J Neurol"},{"issue":"06","key":"ref90","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1212\/NXI.0000000000001063","article-title":"Vascular involvement in neurosarcoidosis: early experiences from intracranial vessel wall imaging","volume":"8","author":"G Bathla","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"07","key":"ref91","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3174\/ajnr.A5492","article-title":"Cerebrovascular manifestations of neurosarcoidosis: an underrecognized aspect of the imaging spectrum","volume":"39","author":"G Bathla","year":"2018","journal-title":"AJNR Am J Neuroradiol"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1055\/s-0040-1713084","article-title":"Metabolic and endocrine challenges","volume":"42","author":"G Martucci","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"issue":"03","key":"ref93","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/0897190019834771","article-title":"Management of endocrine emergencies in the ICU","volume":"32","author":"J Jacobi","year":"2019","journal-title":"J Pharm Pract"},{"issue":"05","key":"ref94","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3390\/jcm13051250","article-title":"Clinical pharmacology in sarcoidosis: how to use and monitor sarcoidosis medications","volume":"13","author":"S Kwon","year":"2024","journal-title":"J Clin Med"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.autrev.2014.10.006","article-title":"The spectrum of opportunistic diseases complicating sarcoidosis","volume":"14","author":"Y Jamilloux","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"49","key":"ref96","doi-asserted-by":"crossref","first-page":"e8846","DOI":"10.1097\/MD.0000000000008846","article-title":"Severe infections in sarcoidosis: Incidence, predictors and long-term outcome in a cohort of 585 patients","volume":"96","author":"A Dur\u00e9ault","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"02","key":"ref97","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/jcm13020342","article-title":"Infectious complications of pulmonary sarcoidosis","volume":"13","author":"D Valeyre","year":"2024","journal-title":"J Clin Med"},{"issue":"15","key":"ref98","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1212\/WNL.0000000000000318","article-title":"Progressive multifocal leukoencephalopathy in patients with sarcoidosis","volume":"82","author":"Y Jamilloux","year":"2014","journal-title":"Neurology"},{"issue":"06","key":"ref99","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamaneurol.2023.0841","article-title":"Characteristics of progressive multifocal leukoencephalopathy associated with sarcoidosis without therapeutic immune suppression","volume":"80","author":"C RS McEntire","year":"2023","journal-title":"JAMA Neurol"},{"issue":"09","key":"ref100","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"J X Li","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"05","key":"ref101","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/M20-0432","article-title":"Association between oral corticosteroid bursts and severe adverse events : a nationwide population-based cohort study","volume":"173","author":"T C Yao","year":"2020","journal-title":"Ann Intern Med"},{"issue":"11","key":"ref102","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1007\/s00134-019-05754-3","article-title":"The effect of systemic corticosteroids on the incidence of gastrointestinal bleeding in critically ill adults: a systematic review with meta-analysis","volume":"45","author":"E Butler","year":"2019","journal-title":"Intensive Care Med"},{"issue":"01","key":"ref103","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-021-00252-7","article-title":"Adrenal insufficiency","volume":"7","author":"S Hahner","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"04","key":"ref104","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.emc.2023.06.006","article-title":"Adrenal emergencies","volume":"41","author":"R E Bridwell","year":"2023","journal-title":"Emerg Med Clin North Am"},{"issue":"02","key":"ref105","doi-asserted-by":"crossref","first-page":"e9088","DOI":"10.1371\/journal.pone.0009088","article-title":"Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations","volume":"5","author":"N J Sweiss","year":"2010","journal-title":"PLoS One"},{"issue":"01","key":"ref106","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ccm.2023.08.008","article-title":"Hematologic and oncologic aspects of sarcoidosis: some of the least studied but most common dilemmas","volume":"45","author":"E E Lower","year":"2024","journal-title":"Clin Chest Med"},{"issue":"01","key":"ref107","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/1744666X.2023.2274363","article-title":"Hematological involvement in sarcoidosis: from cytopenias to lymphoma","volume":"20","author":"P Brito-Zer\u00f3n","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"595077","DOI":"10.3389\/fmed.2021.595077","article-title":"Unsupervised clustering reveals sarcoidosis phenotypes marked by a reduction in lymphocytes relate to increased inflammatory activity on 18FDG-PET\/CT","volume":"8","author":"C Vagts","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"01","key":"ref109","first-page":"e2023008","article-title":"Systematic review of the diagnostic role of neutrophil to lymphocyte ratio in sarcoidosis","volume":"40","author":"M Ghasempour Alamdari","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"ref110","first-page":"jnnp-2021-326267","article-title":"Tumour necrosis factor inhibitor monotherapy for CNS neurosarcoidosis","author":"J M Gelfand","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"06","key":"ref111","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"R P Baughman","year":"2021","journal-title":"Eur Respir J"},{"issue":"05","key":"ref112","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MCP.0000000000000896","article-title":"The treatment of sarcoidosis: translating the European respiratory guidelines into clinical practice","volume":"28","author":"M A Judson","year":"2022","journal-title":"Curr Opin Pulm Med"},{"issue":"05","key":"ref113","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/MCP.0000000000000906","article-title":"Hit-hard and early versus step-up treatment in severe sarcoidosis","volume":"28","author":"A DM Vorselaars","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"ref114","doi-asserted-by":"crossref","first-page":"991783","DOI":"10.3389\/fmed.2022.991783","article-title":"Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"O N Obi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"103179","DOI":"10.1016\/j.jaut.2024.103179","article-title":"Developmental drugs for sarcoidosis","volume":"149","author":"O N Obi","year":"2024","journal-title":"J Autoimmun"},{"issue":"05","key":"ref116","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/MCP.0000000000001196","article-title":"New therapeutic options in sarcoidosis","volume":"31","author":"H Nunes","year":"2025","journal-title":"Curr Opin Pulm Med"},{"issue":"04","key":"ref117","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.chest.2024.10.040","article-title":"Sarcoidosis treatment patterns in the United States: 2016-2022","volume":"167","author":"R Sangani","year":"2025","journal-title":"Chest"},{"key":"ref118","doi-asserted-by":"crossref","first-page":"105811","DOI":"10.1016\/j.clineuro.2020.105811","article-title":"Sarcoidosis of the central nervous system: safety and efficacy of treatment, and experience of biological therapies","volume":"194","author":"D P Kidd","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"08","key":"ref119","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00415-025-13242-6","article-title":"Comparing the efficacy and safety of cyclophosphamide, infliximab and methotrexate in neurosarcoidosis: a multicenter retrospective study","volume":"272","author":"H Gomez","year":"2025","journal-title":"J Neurol"},{"issue":"07","key":"ref120","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1007\/s00415-021-10421-z","article-title":"Effects of immunotherapies and clinical outcomes in neurosarcoidosis: a retrospective cohort study","volume":"268","author":"T Arun","year":"2021","journal-title":"J Neurol"},{"issue":"24","key":"ref121","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1212\/WNL.0000000000003431","article-title":"Treatment of neurosarcoidosis: a comparative study of methotrexate and mycophenolate mofetil","volume":"87","author":"S Bitoun","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"ref122","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1001\/jamaneurol.2017.2492","article-title":"Association of Prognostic Factors and Immunosuppressive Treatment With Long-term Outcomes in Neurosarcoidosis","volume":"74","author":"B Joubert","year":"2017","journal-title":"JAMA Neurol"},{"issue":"03","key":"ref123","doi-asserted-by":"crossref","first-page":"105513","DOI":"10.1016\/j.jbspin.2022.105513","article-title":"Cyclophosphamide for the treatment of central neurosarcoidosis: retrospective study in 32 patients","volume":"90","author":"W Bigot","year":"2023","journal-title":"Joint Bone Spine"},{"issue":"10","key":"ref124","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/thorax-2025-223014","article-title":"Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis","volume":"80","author":"K Bechman","year":"2025","journal-title":"Thorax"},{"issue":"02","key":"ref125","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/acn3.51968","article-title":"Infliximab in neurosarcoidosis: a systematic review and meta-analysis","volume":"11","author":"S Chaiyanarm","year":"2024","journal-title":"Ann Clin Transl Neurol"},{"key":"ref126","doi-asserted-by":"crossref","first-page":"1213448","DOI":"10.3389\/fimmu.2023.1213448","article-title":"Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders","volume":"14","author":"N Gonzalez Caldito","year":"2023","journal-title":"Front Immunol"},{"issue":"09","key":"ref127","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/1744666X.2016.1181541","article-title":"Advances in understanding the immunopathology of sarcoidosis and implications on therapy","volume":"12","author":"F Cinetto","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"123018","DOI":"10.1016\/j.jns.2024.123018","article-title":"Adalimumab as treatment for neurosarcoidosis: a case series","volume":"460","author":"J Shen","year":"2024","journal-title":"J Neurol Sci"},{"issue":"01","key":"ref129","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12931-024-02758-6","article-title":"Efficacy and safety of Infliximab in systemic sarcoidosis according to GenPhenReSa organ-involvement phenotype: a retrospective study of 55 patients","volume":"25","author":"E Rivi\u00e8re","year":"2024","journal-title":"Respir Res"},{"issue":"03","key":"ref130","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/RHU.0000000000002072","article-title":"Tumor necrosis factor inhibitors as early steroid-sparing therapy for neurosarcoidosis: a case series","volume":"30","author":"T Morrison","year":"2024","journal-title":"J Clin Rheumatol"},{"issue":"04","key":"ref131","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1007\/s00415-021-10793-2","article-title":"Adalimumab for CNS sarcoidosis: single-center experience and literature review","volume":"269","author":"S K Hutto","year":"2022","journal-title":"J Neurol"},{"issue":"05","key":"ref132","doi-asserted-by":"crossref","first-page":"e847","DOI":"10.1212\/NXI.0000000000000847","article-title":"Infliximab treatment in pathology-confirmed neurosarcoidosis","volume":"7","author":"D Fritz","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"20","key":"ref133","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1212\/WNL.0000000000004644","article-title":"Infliximab for the treatment of CNS sarcoidosis: a multi-institutional series","volume":"89","author":"J M Gelfand","year":"2017","journal-title":"Neurology"},{"issue":"05","key":"ref134","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00415-017-8444-9","article-title":"Long-term outcomes of refractory neurosarcoidosis treated with infliximab","volume":"264","author":"F Cohen Aubart","year":"2017","journal-title":"J Neurol"},{"issue":"05","key":"ref135","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00415-019-09234-y","article-title":"Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment","volume":"266","author":"Q Riller","year":"2019","journal-title":"J Neurol"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/17562864231205954","article-title":"Defining the course of neurosarcoidosis according to presentation at onset and disease modifying treatment: a cohort study of 84 patients","volume":"16","author":"I Bekkour","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"issue":"01","key":"ref137","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cardfail.2020.08.013","article-title":"Clinical and imaging response to tumor necrosis factor alpha inhibitors in treatment of cardiac sarcoidosis: a multicenter experience","volume":"27","author":"N A Gilotra","year":"2021","journal-title":"J Card Fail"},{"issue":"23","key":"ref138","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1001\/jama.2021.21316","article-title":"Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial","volume":"326","author":"S W Syversen","year":"2021","journal-title":"JAMA"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","article-title":"Immunogenicity of TNF-inhibitors","volume":"11","author":"S Atiqi","year":"2020","journal-title":"Front Immunol"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuropharm.2014.10.027","article-title":"Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability","volume":"96","author":"A Vezzani","year":"2015","journal-title":"Neuropharmacology"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1400533","DOI":"10.3389\/fimmu.2024.1400533","article-title":"The impact of interleukin-6 (IL-6) and mesenchymal stem cell-derived IL-6 on neurological conditions","volume":"15","author":"I Kerkis","year":"2024","journal-title":"Front Immunol"},{"key":"ref142","first-page":"100004","article-title":"Tocilizumab in sarcoidosis patients failing steroid sparing therapies and anti-TNF agents","volume":"1","author":"M Sharp","year":"2019","journal-title":"Respir Med X"},{"issue":"05","key":"ref143","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/rheumatology\/kead373","article-title":"A double-blind, placebo-controlled, randomized withdrawal trial of sarilumab for the treatment of glucocorticoid-dependent sarcoidosis","volume":"63","author":"M C Baker","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.seizure.2022.06.012","article-title":"Anakinra and tocilizumab in the chronic phase of febrile infection-related epilepsy syndrome (FIRES): effectiveness and safety from a case-series","volume":"100","author":"A Aledo-Serrano","year":"2022","journal-title":"Seizure"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"741244","DOI":"10.3389\/fneur.2022.741244","article-title":"Targeting inflammatory mediators in epilepsy: a systematic review of its molecular basis and clinical applications","volume":"13","author":"G Costagliola","year":"2022","journal-title":"Front Neurol"},{"issue":"04","key":"ref146","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s13311-016-0442-6","article-title":"Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study","volume":"13","author":"W J Lee","year":"2016","journal-title":"Neurotherapeutics"},{"issue":"01","key":"ref147","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","article-title":"Rituximab in neurological disease: principles, evidence and practice","volume":"19","author":"D H Whittam","year":"2019","journal-title":"Pract Neurol"},{"issue":"05","key":"ref148","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1183\/09031936.00224513","article-title":"Rituximab in the treatment of refractory pulmonary sarcoidosis","volume":"43","author":"N J Sweiss","year":"2014","journal-title":"Eur Respir J"},{"issue":"01","key":"ref149","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clim.2011.04.005","article-title":"Treatment of multiple sclerosis with anti-CD20 antibodies","volume":"142","author":"B Barun","year":"2012","journal-title":"Clin Immunol"},{"issue":"10","key":"ref150","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","article-title":"New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches","volume":"3","author":"R P Baughman","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"08","key":"ref151","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00415-025-13209-7","article-title":"Rituximab in pathologically confirmed sarcoidosis affecting the central nervous system: a multi-center retrospective study","volume":"272","author":"S K Hutto","year":"2025","journal-title":"J Neurol"},{"issue":"01","key":"ref152","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.autrev.2005.05.006","article-title":"Rituximab: a promising therapy in systemic lupus erythematosus","volume":"5","author":"A Thatayatikom","year":"2006","journal-title":"Autoimmun Rev"},{"key":"ref153","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2147\/ITT.S255722","article-title":"B-Cell targeted treatments for neuromyelitis optica spectrum disorder: a focus on CD19 and CD20","volume":"10","author":"M Levy","year":"2021","journal-title":"ImmunoTargets Ther"},{"issue":"06","key":"ref154","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.anai.2023.01.018","article-title":"Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab","volume":"130","author":"T S Athni","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"17","key":"ref155","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1001\/jama.2023.3954","article-title":"Screening for latent tuberculosis infection in adults: updated evidence report and systematic review for the US preventive services task force","volume":"329","author":"D E Jonas","year":"2023","journal-title":"JAMA"},{"issue":"06","key":"ref156","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"G E Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"04","key":"ref157","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.1212\/WNL.0000000000011218","article-title":"Paraneoplastic myeloneuropathies","volume":"96","author":"S Shah","year":"2021","journal-title":"Neurology"},{"issue":"05","key":"ref158","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3026(25)00049-3","article-title":"Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9)","volume":"12","author":"M Mikulska","year":"2025","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref159","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s13075-019-1996-6","article-title":"Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazole","volume":"21","author":"J W Park","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"02","key":"ref160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1001\/jama.2023.9844","article-title":"Prophylaxis against Pneumocystis jirovecii pneumonia in adults","volume":"330","author":"S Zhou","year":"2023","journal-title":"JAMA"},{"issue":"01","key":"ref161","first-page":"187","article-title":"The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: a review of the literature","volume":"93","author":"A Wang","year":"2020","journal-title":"Yale J Biol Med"},{"issue":"02","key":"ref162","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"M A Friedman","year":"2021","journal-title":"Lung"},{"issue":"03","key":"ref163","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s13760-024-02680-0","article-title":"Tofacitinib as maintenance therapy for refractory neurosarcoidosis","volume":"125","author":"M CF de Melo Bandeira","year":"2025","journal-title":"Acta Neurol Belg"},{"issue":"06","key":"ref164","doi-asserted-by":"crossref","first-page":"e200028","DOI":"10.1212\/NXI.0000000000200028","article-title":"Pachymeningitis in biopsy-proven sarcoidosis: clinical course, radiographic findings, response to treatment, and long-term outcomes","volume":"9","author":"P A Chakales","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"17","key":"ref165","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.3390\/jcm13175069","article-title":"A comprehensive characterization of patients with spinal cord neurosarcoidosis: a single center cross-sectional study of clinical outcomes","volume":"13","author":"R Al-Hader","year":"2024","journal-title":"J Clin Med"},{"issue":"04","key":"ref166","doi-asserted-by":"crossref","first-page":"e1170","DOI":"10.1212\/NXI.0000000000001170","article-title":"Neurosarcoidosis of the cauda equina: clinical course, radiographic and electrodiagnostic findings, response to treatment, and outcomes","volume":"9","author":"G A Bou","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"03","key":"ref167","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1007\/s00415-022-11488-y","article-title":"Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective","volume":"270","author":"M Filippi","year":"2023","journal-title":"J Neurol"},{"issue":"02","key":"ref168","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"D S Reich","year":"2018","journal-title":"N Engl J Med"},{"issue":"03","key":"ref169","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.nic.2024.03.001","article-title":"Diagnostic criteria for multiple sclerosis, neuromyelitis optica spectrum disorders, and myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disease","volume":"34","author":"M Filippi","year":"2024","journal-title":"Neuroimaging Clin N Am"},{"issue":"02","key":"ref170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"D M Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"04","key":"ref171","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1212\/CON.0000000000001454","article-title":"NMOSD and MOGAD","volume":"30","author":"E Sechi","year":"2024","journal-title":"Continuum (Minneap Minn)"},{"issue":"03","key":"ref172","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"B Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"01","key":"ref173","doi-asserted-by":"crossref","first-page":"e209321","DOI":"10.1212\/WNL.0000000000209321","article-title":"Validation of the 2023 international diagnostic criteria for MOGAD in a selected cohort of adults and children","volume":"103","author":"J A Varley","year":"2024","journal-title":"Neurology"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"jnnp-2025-336684","DOI":"10.1136\/jnnp-2025-336684","article-title":"MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis","author":"S B Syc-Mazurek","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"05","key":"ref175","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/pn-2023-003875","article-title":"Neurological involvement by Beh\u00e7et's syndrome: clinical features, diagnosis, treatment and outcome","volume":"23","author":"D P Kidd","year":"2023","journal-title":"Pract Neurol"},{"issue":"02","key":"ref176","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00296-023-05461-9","article-title":"Primary angiitis of the CNS and ANCA-associated vasculitis: from pathology to treatment","volume":"44","author":"A Sherri","year":"2024","journal-title":"Rheumatol Int"},{"issue":"10","key":"ref177","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.neurol.2022.05.003","article-title":"Diagnostic and therapeutic approach to adult central nervous system vasculitis","volume":"178","author":"A Nehme","year":"2022","journal-title":"Rev Neurol (Paris)"},{"issue":"06","key":"ref178","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMra1104650","article-title":"IgG4-related disease","volume":"366","author":"J H Stone","year":"2012","journal-title":"N Engl J Med"},{"issue":"02","key":"ref179","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/jamaneurol.2024.3947","article-title":"Clinical presentation, investigation findings, and outcomes of IgG4-related pachymeningitis: a systematic review","volume":"82","author":"S Terrim","year":"2025","journal-title":"JAMA Neurol"},{"issue":"04","key":"ref180","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1212\/CON.0000000000001005","article-title":"Neurologic complications of tuberculosis","volume":"27","author":"D Saylor","year":"2021","journal-title":"Continuum (Minneap Minn)"},{"issue":"04","key":"ref181","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/WCO.0000000000001358","article-title":"Tuberculosis of the central nervous system: current concepts in diagnosis and treatment","volume":"38","author":"R K Garg","year":"2025","journal-title":"Curr Opin Neurol"},{"issue":"02","key":"ref182","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/jon.13177","article-title":"Pediatric and adult meningeal, parenchymal, and spinal tuberculosis: a neuroimaging review","volume":"34","author":"L Mertiri","year":"2024","journal-title":"J Neuroimaging"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"117325","DOI":"10.1016\/j.jns.2021.117325","article-title":"CNS fungal infections: a review","volume":"422","author":"C L Nathan","year":"2021","journal-title":"J Neurol Sci"},{"issue":"04","key":"ref184","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1212\/CON.0000000000001016","article-title":"Meningitis","volume":"27","author":"A J Aksamit Jr.","year":"2021","journal-title":"Continuum (Minneap Minn)"},{"issue":"10","key":"ref185","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMra2032996","article-title":"Chronic meningitis","volume":"385","author":"A J Aksamit","year":"2021","journal-title":"N Engl J Med"},{"issue":"05","key":"ref186","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1093\/cid\/ciad437","article-title":"State-of-the-art review: neurosyphilis","volume":"78","author":"M M Hamill","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref187","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1212\/CON.0000000000001356","article-title":"Central nervous system lymphoma","volume":"29","author":"L Schaff","year":"2023","journal-title":"Continuum (Minneap Minn)"},{"issue":"03","key":"ref188","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/biomedicines13030659","article-title":"Meningioma: novel diagnostic and therapeutic approaches","volume":"13","author":"C A Yuen","year":"2025","journal-title":"Biomedicines"},{"issue":"21","key":"ref189","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2217\/fon-2018-0006","article-title":"An overview of meningiomas","volume":"14","author":"R A Buerki","year":"2018","journal-title":"Future Oncol"},{"issue":"06","key":"ref190","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.3390\/curroncol30060442","article-title":"Leptomeningeal metastasis: a review of the pathophysiology, diagnostic methodology, and therapeutic landscape","volume":"30","author":"A Nguyen","year":"2023","journal-title":"Curr Oncol"},{"issue":"09","key":"ref191","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11864-020-00771-7","article-title":"Optimal management of corticosteroids in patients with intracranial malignancies","volume":"21","author":"K S Dixit","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"970168","DOI":"10.3389\/fneur.2022.970168","article-title":"Epidemiology, clinical presentation, treatment, and outcome of neurosarcoidosis: a mono-centric retrospective study and literature review","volume":"13","author":"P Sambon","year":"2022","journal-title":"Front Neurol"},{"issue":"08","key":"ref193","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/jnnp-2020-325665","article-title":"TNF-\u03b1 inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis","volume":"92","author":"F Hilezian","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"594133","DOI":"10.3389\/fmed.2020.594133","article-title":"Emerging molecular targets for the treatment of refractory sarcoidosis","volume":"7","author":"G Boleto","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S192922","article-title":"Refractory sarcoidosis: a review","volume":"16","author":"T El Jammal","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"01","key":"ref196","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"W Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"176403","DOI":"10.1016\/j.ejphar.2024.176403","article-title":"Ruxolitinib attenuates microglial inflammatory response by inhibiting NF-\u03baB\/MAPK signaling pathway","volume":"968","author":"J Min","year":"2024","journal-title":"Eur J Pharmacol"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2768-3052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T23:34:40Z","timestamp":1767656080000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2768-3052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":196,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2026,1,5]]},"published-print":{"date-parts":[[2025,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2768-3052","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,10]]},"published":{"date-parts":[[2025,12]]}}}